White House Cuts Quantum Crypto Deadline to 2030
A new executive order moves the post-quantum crypto deadline for high-value federal systems from 2035 to 2030, five years faster than planned.
Morning Brief — June 25, 2026. A Phase 3 death toll collapses ADC Therapeutics, a supply chain breach leaks 200,000 Apple design files, and the White House cuts the post-quantum cryptography deadline to 2030 — compressing five years of compliance runway overnight.
Twenty-seven deaths in ADC Therapeutics' Zynlonta confirmatory trial wiped out 66% of the company's market capitalization and triggered a 17% reduction in its global workforce.
World Leaks posted 200,000 files from Tata's Apple supply chain breach, exposing iPhone schematics and PCB designs; Dell and Nike were previously targeted in the same campaign.
TermScout analysis finds 92% of AI SaaS contracts claim data rights beyond service delivery, meaning most enterprise signups functioned as AI training licenses without explicit consent.
A new executive order cuts the post-quantum cryptography migration deadline for high-value federal systems from 2035 to 2030, giving agencies five fewer years to complete the transition.
Alibaba sued the Pentagon in San Jose on June 23, contesting its Section 1260H military blacklist designation as a due-process violation with a DoD contract ban effective June 30.
A new executive order moves the post-quantum crypto deadline for high-value federal systems from 2035 to 2030, five years faster than planned.
Gilead's remdesivir and Mapp's MBP134 enter their first DRC trial against Bundibugyo ebolavirus, where 277 have died and no licensed treatment exists.
Twenty-seven deaths in Zynlonta's Phase 3 confirmatory trial wiped out 66% of ADC Therapeutics' market cap and 17% of its workforce.
When a cleanroom operator's neck swab came back at 83 colony-forming units, Jubilant's sterile plant had already been sitting on the trend for months.
TermScout analysis: 92% of AI contracts claim data rights beyond service delivery. You signed an AI training license at SaaS onboarding.
Judge Jackson's expedited CFPB remand pits a 556-employee restructuring plan against a $677M injunction compliance gap and new funding caps.
Alibaba sued the Pentagon in San Jose on June 23, claiming its Section 1260H designation violates due process, with a DoD contract ban due June 30.
World Leaks posted 200,000 files from Tata's breach, including Apple iPhone schematics and PCB designs. Dell and Nike were the warm-up.
Walmart's undisclosed Vibe.co deal plugs the SMB gap in its CTV stack, coming one day after it unified ad ops across Walmart Connect and Sam's Club.
Lilly converts a $1.4B milestone obligation into a $50M clean platform buy; Sangamo's Chapter 11 shows how bankruptcy reshapes deal math.
Jubair, 20, faces a US indictment over 120 intrusions and $115M in ransom, but the UK's six-week trial never made it past opening arguments.
Anthropic starts scanning government IDs on July 8. Consumers face biometric checks, but the API exemption reveals the real dividing line.
Exelixis' zanzalintinib missed OS in the NLM subgroup, putting roughly half of a $1.3B peak-sales estimate at stake before the Dec. 3 FDA call.
LSD-based DT120 beat placebo by 8.1 MADRS points and held the gain through week 12. Definium's FDA submission just got a lot more credible.
OCC's Bank Secrecy Act rule for stablecoin issuers arrived the same week five agencies jointly proposed mandatory KYC for the same companies.
With the CFPB retreating, NJ AG Davenport's $20K-per-violation junk-fee blueprint may hand every state AG a ready-made enforcement map.
Nuvectis paid $40M upfront for ex-China rights to Haisco's once-daily Factor B inhibitor in a PNH market projected above $5B in 2026.
Polymarket staged $900K in fake wins for banned US users using copycat sites and a hired creator network. Its second marketing scandal in three weeks.
SK Biopharmaceuticals is putting $18M upfront on a $2.5B Insilico neuroimmune deal — and the backloaded structure tells you who blinked.
Four state AGs are probing FIFA's World Cup tickets: seat bait-and-switch, sky-high variable pricing, and no consumer disclosure framework.